ArticleThe Journal of biological chemistry2026
The stress-activated kinase p38 mediates non-canonical activation of Src and tyrosine phosphorylation of the adapter protein TAB1.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Src is a non-receptor tyrosine kinase that is overexpressed and highly activated in many cancers and is one of the key factors contributing to malignant transformation. According to current concepts, Src activity relies on tyrosine phosphorylation, and phospho(p) Y419 in the activation loop is often regarded as a marker of its activation. However, recent studies have shown that pY419 may contribute to substrate selection. Therefore, the mechanisms underlying Src activation other than classical tyrosine phosphorylation warrant further study. We herein demonstrated that Src phosphorylates a novel substrate, TAB1, directly at Y481 in the TAK1-binding domain, changing the TAK1-TAB1 interaction. p38 enhances Src-mediated TAB1 phosphorylation through the direct phosphorylation of Src at N-terminal S75. Moreover, the mode of substrate recognition by the SH2 domain of Src is different in TAB1 than in FAK, a known SH2-dependent substrate. The present results identify a novel non-canonical Src activation mechanism based on serine phosphorylation and suggest pY481-TAB1 and pS75-Src as improved markers of Src activation, thereby offering alternative modes for assessing the Src activation status of Src-dependent cancers before and during targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.